Leadership & Governance

German, Micro-Biologist, >25 years of experience in Bio- pharma, “Entrepreneur of the Year” (E&Y), winner “Excellence in Financing Growth (EU Commission).

Investor in Biotech & Digital health. Personal Advisor to several CEOs, member of Advisory Boards of PE-, Biotech- & start-up-companies. Extensive global C-level network in Biopharma & Capital.

Professional Track Record:

• 2010 to current: shareholder subrosa health group
• 1999-2010: pharmexx (CSO) CEO, main shareholder, one of the most successful small caps in EU, World´s No.1 CSO (5,500 employees, 21 countries), divestment in 2010, now “Ashfield/Inizio”.
• 1993-1999: Sales and Mgmt. roles in biopharma (Zeneca, BMS)

Ronald is Managing Partner and founding CEO of Anrontt - a firm that provides advisory and consulting services in Strategy and Transformation in the HR domain. Ronald also serves on the board of corporates as an independent director besides being an adviser/consultant across various industries – Pharma, Retail, Cosmetics, Medical Devices, Financial services, Facilities Management, etc.

Ronald joined GlaxoSmithKline (GSK) Pharma India in December 2006 and was appointed Executive Director on the Board of Directors in October 2007. Ronald used to oversee HR for South Asia and Country HR Head India till end December 2018. Ronald was also a Director on the Board of Chiron Bearing Vaccines Pvt Limited and Biddle Sawyer Ltd, a GSK subsidiary.

Ronald began his HR career as a Management Trainee of Union Carbide India Limited and rose rapidly to head their flagship unit in HR. In 1992 Ronald joined HSBC as Head-HR for Eastern India. From there on he held several positions of increasing responsibilities including driving HSBC India’s growth agenda between 1998 and 2002 before being moved to HSBC Hong Kong as Manager Asia Pacific. At HSBC he played a significant HR role in setting up HSBC Call centre, Retail banking, Factoring services, Cash management services, Credit cards etc and was co-opted on the project team to set up HSBC’s outsourcing operations and IT services in India.

In 2004 Ronald joined Tata Power as Vice President & Head HR where in addition to the HR function he had oversight of its large CSR function. He was also a member of the Group HR steering committee for the Tata Group.

Ronald’s career is marked by several significant achievements in the areas of performance management, change management, total quality management, employee relations, and organizational restructuring. He has a proven track record of improving employee communications and feedback mechanisms.

Ronald was the chairman of the Western Region HR committee of CII (Confederation of Indian Industry – 2009 - 2011) and is a member of the National Committee for Employee Relations and the Skills building committee. Ronald is on the Board of Studies for the Pharma MBA programme, HR programme and the Pharma tech programme of NMIMS, Mumbai. Ronald has been on the Board of Governors for Indian School of Business & Media, Pune. Ronald has also been a visiting faculty. Ivey Publishing - Ivey Business School has also published Ronald’s case study on re-inventing incentives and performance.

Business Transformation | Disruptive Marketing Specialist | Rare Disease & Orphan Drugs Specialist

Chenthir’s remarkable career is a Paragon of success, Inspiring others to strive for greatness. Through innovative & Strategic mindset he has led to significant improvement’s and positive impact in the bottom-line results of several organizations.

His unique approach is characterized by an unwavering dedication to deliver superior service and customized solutions that meet the precise needs of his clients.

As a socially responsible business leader, Chenthir has made a profound impact on the lives of thousands of individuals by creating employment opportunity and fostering a culture of professional growth and development.

Premier Awards & Recognitions:

• “Rashtriya Rattan Award” & “Pride of India Award 2005”: Conferred by Global Economics Council, New Delhi, for his outstanding individual achievements & distinguished services to the nation.
• WHO’s WHO list of Historical Society of USA: Having demonstrated exemplary achievement & distinguished contributions to the business community, The International WHO’s WHO Historical Society of USA has recognized him as an outstanding professional & listed his name in their 2005-2006 edition of International WHO’s WHO.
• “Best Start Up Company – 2007”: Awarded to csmo Pharmexx (India) Pvt. Ltd. given by Pharmexx GmbH in the year 2008.
• “Outstanding Entrepreneurship Award – 2010”: Given by Enterprise Asia (a non-governmental organisation for entrepreneurship).
• “Hall of Fame 2010”: Human Factor Magazine.
• “PowerBrands Hall of Fame – Global Achievers” Award 2012-13.

Dr. Raktim Chattopadhyay, is a distinguished scientist, entrepreneur, and thought leader in the field of oncology and medical nutrition. As the Founder and CEO of Esperer, he has pioneered an innovative approach to cancer care by integrating molecular nutrition science with biosensitivity-driven therapeutic strategies. His work bridges cutting-edge research, translational medicine, and clinical practice, reshaping how nutritional interventions are designed and delivered in oncology.

With a doctorate in cancer Biology with multiple global patents in his name, Dr. Chattopadhyay has authored numerous scientific articles and white papers on biosensitivity-based nutrition, cancer metabolism, and therapeutic innovation. His contributions have been widely recognized for advancing the role of precision nutrition in cancer management.

Under his leadership, Esperer Onco Nutrition has emerged as a global trailblazer, developing evidence-based, clinically validated nutrition platforms that support patients across cancer care pathways. His vision is centered on making oncology nutrition an indispensable pillar of integrative cancer treatment, thereby improving patient outcomes, quality of life, and long-term survivorship.

A sought-after speaker and strategic advisor, Dr. Chattopadhyay regularly engages with academic institutions, clinical research bodies, and healthcare policymakers worldwide. He is also actively involved in global collaborations that shape the future of personalized nutrition, sustainable healthcare innovation, and accessibility in emerging markets.

Driven by a strong sense of mission, Dr. Chattopadhyay continues to champion the convergence of science, technology, and compassionate care, ensuring that cancer patients worldwide benefit from next-generation nutritional science tailored to their unique biological needs.

Driving the development of healthcare programmes that connect patient needs with practical pathways for action.

With over 16 years of experience in healthcare, Dr. Wadhwa has worked across rare diseases, market access, commercial strategy, business development and stakeholder engagement. Her professional experience includes building new divisions, developing patient access pathways, working with healthcare institutions and coordinating cross-functional teams across medical, regulatory, access and commercial functions.

Her work in rare diseases has involved engagement with clinicians, patient groups, regulatory stakeholders and global healthcare partners, along with experience in Named Patient Programmes and access initiatives.

At Healing Wings Foundation, Dr. Wadhwa focuses on developing programmes and initiatives that respond to unmet healthcare needs. She coordinates the Foundation's programme development, including Care for Rare, and works on identifying opportunities for CSR-supported healthcare initiatives.

She is particularly interested in the intersection of patient needs, healthcare access, research and innovation, and in building practical models that can bring different parts of the healthcare ecosystem together.

Anil Raina is a senior biopharma executive and rare-disease leader with nearly three decades of experience across the pharmaceutical and life sciences sectors. In his most recent leadership role at Sanofi, he served as General Manager, Specialty Care, India & South Asia, leading a business focused on bringing innovative therapies to patients across the region. His career has spanned rare diseases and other specialty-care areas, giving him a distinctive perspective at the intersection of science, healthcare, access and patient needs.

He has worked closely with patients and families, clinicians, Centres of Excellence, policymakers and industry partners to address critical challenges across the rare-disease continuum—from awareness and diagnosis to access to treatment and long-term support. His expertise spans strategy, commercialisation, market access and the delivery of innovative therapies to patients.

Anil has played an active role in advancing India’s rare-disease ecosystem and contributed to stakeholder discussions supporting the National Policy for Rare Diseases 2021. This experience has given him a nuanced understanding of the systemic barriers facing patients and the importance of coordinated, cross-sector action.

He is committed to strengthening collaboration across the rare-disease community and translating scientific and therapeutic advances into earlier diagnosis, improved access and better outcomes for patients and their families.

Anil holds a B.Tech in Mechanical Engineering and an MBA in International Business.

Anuj Pasrija epitomizes a career dedicated to the credo of "Doing Well by Doing Good." With over 25 years of multifaceted leadership spanning large profit and loss (P&L) ownership, general management, and corporate functional leadership across the MedTech, Pharma, Consumer Products & Retail sectors. Anuj's impact transcends several continents from the United States and Canada to the dynamic markets of Asia and Africa. Renowned for his visionary approach, Anuj has spearheaded groundbreaking initiatives that not only driven commercial growth but also improved access to medicines for millions of under-served communities globally.

His pioneering business innovation in Pharma industry garnered global acclaim, with Harvard Business School recognizing it as a case study authored by Professor Michael Porter. Featured thrice in Fortune magazine's ‘Change the World’ series, Anuj's commitment to driving positive change in healthcare is unwavering. In addition to his corporate leadership roles, Anuj's contributions extend to the boardroom, where he plays a pivotal role in shaping healthcare standards and advancing sustainability initiatives. As a Board Member of large public hospital system, Lakeridge Health, Canada and non-profits like GS1 Canada, the Canadian College of Healthcare Leaders, and the Health Products Stewardship Association Canada, he continues to influence critical decisions that impact future of Canadian healthcare system. His academic pursuits underscore his dedication to continuous learning and innovation.

In addition to being an alumnus of Harvard Medical School, he also holds an MBA from IMI (affiliate IMD Lausanne, Switzerland). Complementing his academic achievements, Anuj has pursued executive education in AI/ML from Harvard and MIT-Sloan.

Globally recognized for his contributions, Anuj is a sought-after speaker at prestigious events, including his talks on access to healthcare for under-privileged communities, at the EU Parliament, WHO Access to Medicines, UN Right to Health, and the UN Global Compact. His leadership journey exemplifies a steadfast commitment to making a positive impact on a global scale, reaffirming his belief that true success of industry lies in co-creating meaningful societal change.

He is a surgeon by training and entrepreneur by mindset. After spending a decade in India in Surgery, he moved to the UK, where he spent another decade in the NHS, where he finished as a Specialist Registrar in Surgery, specialising in vascular and breast surgery. He was also a trainer and tutor with the Royal College of Surgeons of England.

In 2012, he joined the pharmaceutical industry and after spending time in various positions in Medical Affairs, Medical Marketing, Market Access and Pharmacovigilance in companies like Novo Nordisk, Abbott, Eli Lilly and Company, he finished as a Global Director of Human Risk Management at Reckitt and Benckiser. During his tenure, he won the Businessperson of the Year in the Bengal Pride Awards and was a finalist at the Asian Achievers Awards held in London in 2022. He has also served as the Chief Medical Officer of a new start up called TMS Partners which is based in UK, US and Vietnam where he has played a key role in digitising medical services in wellness, genetics services including counselling and remote patient monitoring. He has managed doctors’ network in the US, crafted CMEs, workflow designs, care plans and talking points. He has recruited doctors to expand the network and worked with marketing groups to ensure compliance He has worked with various stakeholders to improve the products and services.

During his tenure in the pharmaceutical industry, he has been involved in the creation of CMEs, Patient Awareness programs and content for Medical Marketing. He has helped start the Eli Lilly Institute for Safety.

He is a Mentor, Investor and Strategic Advisor at iKure, a multi award winning population health management company that is active in the last mile. It works with Community Health Workers and uses digital technology to provide healthcare to villages. Starting 11 years back in the villages of Bengal in India, this has now grown and has a presence in 12 states of India, Bangladesh, S.E. Asia, Middle East and Africa.

He is now the Business and Clinical Head of a new transitional care centre which is coming up in North Bangalore. In keeping with his keen interest in Rare Diseases, which he developed when working with Cystic Fibrosis in Abbott, he is closely associated with the Organisation for Rare Diseases in India and is currently working with Deloitte and with Rare Advocacy Movement based in the US, in order to conduct a Health Technology Assessment to bolster funding to this organisation.

His key skills are leadership, communication and in-depth scientific knowledge. An innovator and change maker he is well-versed in driving change and keeps the wellness of his team as a priority. An erudite speaker, he has been involved in many webinars on a variety of topics. His Alma Maters include the University of Calcutta (Medicine and Surgery), the Royal College of Physicians and Surgeons of Glasgow, Harvard Business School (Medical Innovation), University of Oxford (Health Economics) and Rice University (Digital Health).

Dr Mukund Kamath is recognized as a distinguished expert in Healthcare and Pharma Business Leadership. With a career journey spanning over 2 decades, he has garnered invaluable experience across various business domains within the healthcare and pharmaceutical sectors.

His journey in the healthcare industry is lined with pivotal roles at esteemed organizations such as Zydus Ltd,. Unichem Laboratories Ltd., Pfizer India Ltd., Colgate Middle East, Torrent Pharmaceuticals Ltd. and has transgressed growth for brands such as Shelcal, Gelusil, Becosules and Colgate with diverse exposure to India, Middle East and North African markets.

Apart from his proven success in brand building, Dr Mukund contributed immensely to the Indian pharma by building a talent pool during his tenure as a business and team leader. Dr Mukund is an alumni of the Indian Institute of Management Calcutta, Indian Institute of Management Kozhikode, Dr D Y Patil Vidyapeeth and Lokmanya Tilak Municipal Medical College, by virtue of his educational background – MBBS, M.D. (Preventive Social Medicine) and Executive Education programs in Business Administration and Marketing Management.

Given his rich and diverse experience, he is also a coveted speaker at diverse forums. He is invited regularly to top tier B Schools such as IIM Kozhikode to share his expertise with young minds and young industry leaders. Dr Mukund’ expert opinions are regularly quoted by premier industry magazines of the country and is also a popular choice as panellist for reputed Industry forums such as Indian Pharmaceutical Association, Organization of Pharmaceutical Producers of India and Nutrify Today, to speak on navigating opportunities amidst evolving Consumer and Patient needs.

His work has been well received and recognized by industry bodies through accolades which include the Marketing Thought Leader Award 2013 from CMO Asia and the Marketeer of the Year 2012, 2016 and 2022 from the Asian Confederation of Business.

MBBS (Cal), FCCP, MRIPHH (U.K.), PhD (Diabetology), PG Diploma Diabetology, Post Graduate Program in Diabetology, School of Medicine, Boston University, (USA), Program in Acute Medicine (Royal College of Physicians UK - NHS Education England). Visiting Consultant | Director | Research Presenter

Professional Summary:

A seasoned medical professional with over 28 years of clinical experience in diabetes and critical care. Dr. Sanjay Sud is the Director of Doctor Sud’s Clinic, an esteemed clinic specializing in comprehensive diabetic care. He has made significant contributions in the field of Diabetology through numerous research presentations and papers at both national and international levels.

Also a prolific Echocardiographer performing advanced Echocardiography studies for the last 20 years at various institutions and renowned diagnostic centres (like Suraksha & Medionn) located all over southern West Bengal. Accredited with level 2 Accreditation for advanced echocardiography by the Indian Academy of Echocardiography.

Professional Experience:

• Visiting Consultant: Department of Medicine, Konnagar Municipal Hospital, Hooghly, W.B. India - Provided expert consultations on diabetic patient management and critical care.
• Director: Doctor Sud’s Clinic, Serampore, Hooghly, W.B. India - Leads a comprehensive diabetic clinic catering to the needs of patients across various stages of diabetes, with a focus on critical care.
• Ex Clinical Observer Accident & Emergency, Joyce Green Hospital, Dartford, Kent, England.

Presenter of Original Research Papers & Abstracts:

• International Diabetes Federation (IDF): 2017 (Abu Dhabi), 2019 (Busan), 2022 (Lisbon). Presented seven papers as the sole author, including two oral presentations.
• RSSDI: 2018, 2019, 2022, 2023, and 2024. Presented papers and abstracts at the Research Retreat (6 papers in 2023 and 2 presentations in 2024).
• NAPCON, CRITICARE, EZECHO, DIACON, etc.: Participated with several papers and oral presentations from 2019 through 2024.
• National faculty: RSSDI 2022 (Chennai), 2023 (Mumbai), RSSDI Research Retreat 2023 & 2024, IDEACON 2019, HDSCON 2022, 2023 & 2024, DRWA Conference 2024 & EZECHO 2022.

Awards & Recognitions:

Indian Council of Medical Research Scholar (Forensic Medicine) | IMA Bengal Special appreciation award for contribution to the Medical profession 2023 | Member of various medical societies and research bodies focused on diabetology and critical care.

Results-driven business leader with expertise in developing cutting-edge technologies: medical devices, AI, ML, predictive analytics, defense, photonics, and semiconductor design.

Proven track record in:

1. Incubating 50+ Biotech and Medtech startups from concept to market launch.
2. Driving strategic growth, inspiring innovation, and leading cross-functional teams.
3. Boosting client and research product databases by 400%.
4. Establishing fruitful partnerships with 70+ global organizations, introducing pioneering solutions to India.

Noah Vincent Nagl is a German Biologist [B.Sc. Biology, TU Kaiserslautern] and part of subrosa Health & Capital, Mannheim, as Candidate Relations Consultant & Marketing.

With hands-on experience in pharma field sales [Abdipharma / Pharmxpert - Rivaroxaban generic launch], life sciences executive search, and patient support [Adxto AB, Sweden], he brings a strong mix of scientific understanding + commercial execution.

He is also actively involved in non-profit activities and currently supporting the roll-out of Global Healing Wings Foundation - an initiative focused on rare disease awareness, patient access, and community support.

Senior global biopharmaceutical executive and market access strategist with over 25 years of experience commercializing transformative therapies across rare disease, gene therapy, oncology, specialty pharma, and emerging market access programs. Architect of scalable market entry infrastructure for both established and pre-commercial companies, with 17+ product launches including multiple blockbusters -- Humira, Incivek, Kalydeco, Celebrex, and the full Sarepta DMD portfolio (Exondys 51, Vyondys 53, Amondys 45, Elevidys).

In parallel with executive commercial roles, serves as a strategic global access consultant and advisory board facilitator for emerging biotech clients across CGT, rare disease, and oncology, and as named facilitator for FEAT Healthcare's Africa Advisory Board program spanning Clinical Development, Regulatory, and Commercial & Market Access across Ghana, Nigeria, Kenya, Egypt, and South Africa. Founder of QURA Global and QRx Consulting LLC on NPP/SAP infrastructure design, rare disease access strategy, JV structuring, fundraising, and biotech business development.